MARKET

RANI

RANI

Rani Therapeutics Holdings, Inc.
NASDAQ
0.5601
-0.0142
-2.47%
Pre Market: 0.5872 +0.0271 +4.84% 09:06 11/11 EST
OPEN
0.5600
PREV CLOSE
0.5743
HIGH
0.5788
LOW
0.5400
VOLUME
3.44K
TURNOVER
0
52 WEEK HIGH
2.155
52 WEEK LOW
0.5100
MARKET CAP
78.08M
P/E (TTM)
-2.9952
1D
5D
1M
3M
1Y
5Y
1D
Rani Therapeutics: Buy Rating Reaffirmed on Strong Q3, Extended Cash Runway and RT-114 Catalyst; $5 Price Target Unchanged
TipRanks · 19h ago
Rani Therapeutics reports Q3 EPS (4c), consensus (5c)
TipRanks · 20h ago
Rani Q3 Loss Widens On Higher R&D Expenses; RT-114 Phase 1a Expansion Data Due By Year-End
NASDAQ · 1d ago
Rani Therapeutics Holdings, Inc. Reports Third Quarter 2026 Financial Results and FDA Emerging Technology Program Acceptance
NASDAQ · 1d ago
Rani Therapeutics GAAP EPS of -$0.04, revenue of $1.7M
Seeking Alpha · 1d ago
Weekly Report: what happened at RANI last week (1102-1106)?
Weekly Report · 2d ago
Weekly Report: what happened at RANI last week (1026-1030)?
Weekly Report · 11/02 10:26
Weekly Report: what happened at RANI last week (1019-1023)?
Weekly Report · 10/26 10:25
More
About RANI
Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. The Company has developed the RaniPill capsule, which is a proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. The RaniPill capsule is designed to deliver a variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. It has two configurations of the platform: the RaniPill GO and the RaniPill HC. The RaniPill GO is designed to deliver up to a 3 mg dose of drug in microtablet form with high bioavailability. It is also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC. Its product candidate pipeline includes obesity programs (RT-114 and RT-116), immunology programs (RT-105 and RT-111) and endocrinology programs (RT-102 and RT-110).

Webull offers Rani Therapeutics Holdings Inc stock information, including NASDAQ: RANI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RANI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RANI stock methods without spending real money on the virtual paper trading platform.